NovoCure Limited Q4 2025 Earnings Call Summary [Yahoo! Finance]
NovoCure Limited - Ordinary Shares (NVCR)
Last novocure limited - ordinary shares earnings: 4/30 06:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
novocure.com/investor-relations
Company Research
Source: Yahoo! Finance
NovoCure Limited Q4 2025 Earnings Call Summary - Moby Strategic Execution and Operational Evolution Achieved record net revenue of $655 million in 2025, driven by substantial active patient growth in international markets like France and Japan. Transitioned to a multi-indication platform company following the FDA approval of Optune Pax for locally advanced pancreatic cancer in a record 180-day review cycle. Stabilized the core glioblastoma (GBM) business in mature markets, shifting focus toward high-return potential indications like pancreatic cancer over slower-growing lung cancer segments. Restructured the leadership team by combining scientific and clinical organizations under a dual Chief Innovation and Medical Officer role to accelerate R&D-to-clinical cycles. Leveraged an existing 'torso' sales force to launch Optune Pax, minimizing incremental commercial spend by utilizing established physician relationships in oncology. Addressed a temporary Medicare billing adm
Show less
Read more
Impact Snapshot
Event Time:
NVCR
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NVCR alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NVCR alerts
High impacting NovoCure Limited - Ordinary Shares news events
Weekly update
A roundup of the hottest topics
NVCR
News
- Novocure Announces Optune Lua® Receives Reimbursement Approval in Japan for the Treatment of Non-Small Cell Lung CancerBusiness Wire
- Novocure to Participate in 2026 Leerink Global Healthcare ConferenceBusiness Wire
- NovoCure (NVCR) had its price target raised by HC Wainwright from $47.00 to $49.00. They now have a "buy" rating on the stock.MarketBeat
- NovoCure: Q4 Earnings Snapshot [Yahoo! Finance]Yahoo! Finance
- NovoCure GAAP EPS of -$0.22 beats by $0.19, revenue of $174.35M beats by $0.99M [Seeking Alpha]Seeking Alpha
NVCR
Earnings
- 2/26/26 - Beat
NVCR
Sec Filings
- 3/4/26 - Form 144
- 3/4/26 - Form 144
- 3/4/26 - Form 144
- NVCR's page on the SEC website